Suppr超能文献

儿童体外和连续流心室辅助装置的比较:初步结果。

Comparison of paracorporeal and continuous flow ventricular assist devices in children: preliminary results.

作者信息

Nassar Mohamed S, Hasan Asif, Chila Teresa, Schueler Stephan, Pergolizzi Carola, Reinhardt Zdenka, Lord Stephen, De Rita Fabrizio, Ferguson Lee, Smith Jon, Haynes Simon, O'Sullivan John, Murtuza Bari

机构信息

Department of Paediatric Cardiac Surgery, Anaesthesia & Intensive Care, Freeman Hospital, Newcastle Upon Tyne, UK.

Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle Upon Tyne, UK.

出版信息

Eur J Cardiothorac Surg. 2017 Apr 1;51(4):709-714. doi: 10.1093/ejcts/ezx006.

Abstract

OBJECTIVES

With the scarcity of organs, a durable, reliable ventricular assist device (VAD) is required. The Berlin Heart EXCOR ® (BH) remains the most established VAD in the paediatric population. Implantable continuous flow (CF) VADs have been introduced to the paediatric field with encouraging early results. In this study, we compared the results of a newly introduced CF VAD (HeartWare VAD [HVAD] ® ) to results in a matched group of BH recipients.

METHODS

The study included patients aged <16 years who received mechanical left VAD (LVAD) support between December 2005 and January 2016. The preimplant characteristics and postimplant outcomes of patients who received the HVAD were compared with those of a matched group who received the BH. Patients with congenital heart disease were excluded.

RESULTS

Thirty patients were included in the study: 13 had received the HVAD and were matched with 17 patients who had received the BH LVAD. The only difference in preimplant characteristics was the need for higher inotropic support in the BH group. There was no difference in the need for right ventricular (RV) support (58.8% for BH vs 53.8% for HVAD, P  = 1.00) or in the incidence of cerebrovascular accidents (12.5% vs 7.7%, respectively, P  = 1.00), though the BH group showed prolonged mechanical ventilation (31.3% vs 0%, P  = 0.047). There were no deaths while on VAD support in either group. Patients with the HVAD showed a bimodal distribution for the primary end point (transplant/explant): All HVAD recipients who also required early RV support reached this end point within 30 days of receiving the implant.

CONCLUSIONS

Our early experience with the CF intracorporeal LVAD system (HVAD) indicates outcomes comparable to those with the well-established pulsatile flow paracorporeal LVAD (BH). The theoretical durability of the CF device, which might also allow for the possibility of hospital discharge and better quality of life, is yet to be proven.

摘要

目的

鉴于器官稀缺,需要一种耐用、可靠的心室辅助装置(VAD)。柏林心脏EXCOR®(BH)仍然是儿科人群中最成熟的VAD。可植入式连续血流(CF)VAD已引入儿科领域,早期结果令人鼓舞。在本研究中,我们将一种新引入的CF VAD(HeartWare VAD [HVAD]®)的结果与一组匹配的BH接受者的结果进行了比较。

方法

该研究纳入了2005年12月至2016年1月期间接受机械左心室辅助装置(LVAD)支持的16岁以下患者。将接受HVAD的患者的植入前特征和植入后结果与接受BH的匹配组患者进行比较。排除先天性心脏病患者。

结果

30名患者纳入研究:13名接受了HVAD,并与17名接受BH LVAD的患者匹配。植入前特征的唯一差异是BH组需要更高剂量的强心支持。右心室(RV)支持的需求(BH组为58.8%,HVAD组为53.8%,P = 1.00)或脑血管意外的发生率(分别为12.5%和7.7%,P = 1.00)没有差异,尽管BH组机械通气时间延长(31.3%对0%,P = 0.047)。两组在VAD支持期间均无死亡。HVAD患者的主要终点(移植/取出)呈双峰分布:所有同时需要早期RV支持的HVAD接受者在植入后30天内达到该终点。

结论

我们对CF体内LVAD系统(HVAD)的早期经验表明,其结果与成熟的搏动血流体外LVAD(BH)相当。CF装置的理论耐久性,这也可能允许出院和更好的生活质量,还有待证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验